Department of Dermatology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
J Dermatolog Treat. 2023 Dec;34(1):2252119. doi: 10.1080/09546634.2023.2252119.
Vitiligo is an idiopathic depigmenting skin disorder. The study compares the efficacy of topical tacrolimus 0.1% with calcipotriol/betamethasone dipropionate in vitiligo patients receiving NB-UVB treatment. Forty-one adult patients with generalized type vitiligo were recruited. Patients were assigned to phototherapy and then classified into either group one (20 patients), receiving calcipotriol/betamethasone dipropionate cream (D group), or group two (21 patients), receiving tacrolimus 0.1% ointment (T group). They were followed-up at 3 and 6 months. The D group witnessed an increase in the repigmentation area from 35.4% in the third month to 54.7% in the sixth month ( = 0.001) and the T group from 32.2% to 45.6% ( = 0.011). However, the differences between the treatment groups were not statistically significant. Body sites demonstrated different levels of improvement ranging from the highest in the face to the lowest in the Hand & Feet with the other body sites in between. A negative correlation was identified between the duration since diagnosis and the response to D treatment (3 months: = -0.612, = 0.007; 6 months: = -0.755, = 0.001). Although both combinations are efficacious, they did not significantly differ in efficacy at three and six months follow-up points. The study was registered at clinicaltrials.gov (NCT04440371).
白癜风是一种特发性色素减退性皮肤病。本研究比较了他克莫司 0.1%与卡泊三醇/倍他米松二丙酸酯在接受 NB-UVB 治疗的白癜风患者中的疗效。招募了 41 名患有泛发性白癜风的成年患者。患者被分配接受光疗，然后分为一组（20 名患者），接受卡泊三醇/倍他米松二丙酸酯乳膏（D 组），或二组（21 名患者），接受他克莫司 0.1%软膏（T 组）。他们在 3 个月和 6 个月时进行随访。D 组的复色面积从第 3 个月的 35.4%增加到第 6 个月的 54.7%（ = 0.001），T 组从 32.2%增加到 45.6%（ = 0.011）。然而，治疗组之间的差异没有统计学意义。身体部位的改善程度不同，从面部最高到手和脚最低，其他身体部位介于两者之间。在 D 治疗中，诊断后时间与反应之间存在负相关（3 个月： = -0.612， = 0.007；6 个月： = -0.755， = 0.001）。虽然这两种组合都有效，但在 3 个月和 6 个月的随访点，它们的疗效并没有显著差异。该研究在 clinicaltrials.gov 上注册（NCT04440371）。
